We are live on
!
Find out more
AQR Capital Management Portfolio holdings
AUM
$218B
1-Year Est. Return
29.41%
This Fund
S&P 500
This Quarter
Est. Return
-12.77%
1 Year Est. Return
+29.41%
3 Year Est. Return
+92.15%
5 Year Est. Return
+116.61%
10 Year Est. Return
+435.72%
AUM
$44.2B
AUM Growth
-$8.44B
(-16%)
Cap. Flow
-$301M
Cap. Flow
% of AUM
-0.68%
Top 10 Holdings %
Top 10 Hldgs %
14.01%
Holding
2,360
New
150
Increased
1,005
Reduced
998
Closed
187
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$209M |
| 2 |
CVS Health
CVS
|
+$195M |
| 3 |
Tyson Foods
TSN
|
+$136M |
| 4 |
ExxonMobil
XOM
|
+$135M |
| 5 |
LyondellBasell Industries
LYB
|
+$130M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Thermo Fisher Scientific
TMO
|
+$239M |
| 2 |
Microsoft
MSFT
|
+$204M |
| 3 |
Johnson & Johnson
JNJ
|
+$157M |
| 4 |
Amazon
AMZN
|
+$144M |
| 5 |
Walmart Inc
WMT
|
+$137M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.23% |
| 2 | Healthcare | 16.49% |
| 3 | Financials | 11.74% |
| 4 | Industrials | 11.47% |
| 5 | Consumer Discretionary | 10.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Apple
AAPL
$4.89T
| $1.33B | 3.01% |
9,852,970
-655,488
| -6% | -$99.3M |
|
|
2
Microsoft
MSFT
$2.84T
| $1.2B | 2.7% |
4,692,942
-750,479
| -14% | -$204M |
|
3
Alphabet (Google) Class A
GOOGL
$3.91T
| $620M | 1.4% |
5,754,580
-482,620
| -8% | -$56.8M |
|
4
TSMC
TSM
$2.09T
| $557M | 1.26% |
6,818,131
-157,456
| -2% | -$14.6M |
|
5
Pfizer
PFE
$140B
| $554M | 1.25% |
10,564,755
-138,739
| -1% | -$7.07M |
|
6
Meta Platforms (Facebook)
META
$1.51T
| $437M | 0.99% |
2,738,223
-221,429
| -7% | -$42.7M |
|
|
7
ExxonMobil
XOM
$651B
| $378M | 0.85% |
4,409,523
+1,497,093
| +51% | +$135M |
|
|
8
Gilead Sciences
GILD
$161B
| $376M | 0.85% |
6,095,793
+3,383,767
| +125% | +$209M |
|
9
Procter & Gamble
PG
$343B
| $376M | 0.85% |
2,646,081
-372,423
| -12% | -$56M |
|
10
Merck
MRK
$324B
| $375M | 0.85% |
4,115,421
+508,923
| +14% | +$45.1M |
|
|
11
Johnson & Johnson
JNJ
$635B
| $370M | 0.84% |
2,097,689
-882,307
| -30% | -$157M |
|
|
12
Amazon
AMZN
$2.5T
| $366M | 0.83% |
3,534,618
-1,147,322
| -25% | -$144M |
|
|
13
Alphabet (Google) Class C
GOOG
$3.9T
| $359M | 0.81% |
3,282,240
-291,020
| -8% | -$34.4M |
|
14
PepsiCo
PEP
$186B
| $341M | 0.77% |
2,044,782
+99,586
| +5% | +$16.8M |
|
15
Regeneron Pharmaceuticals
REGN
$68.8B
| $323M | 0.73% |
550,416
+41,635
| +8% | +$27.1M |
|
|
16
CVS Health
CVS
$137B
| $313M | 0.71% |
3,374,381
+2,000,311
| +146% | +$195M |
|
17
UnitedHealth
UNH
$382B
| $308M | 0.7% |
600,297
-191,236
| -24% | -$96M |
|
18
Cisco
CSCO
$450B
| $292M | 0.66% |
6,906,458
+960,181
| +16% | +$46M |
|
|
19
Tyson Foods
TSN
$20.2B
| $278M | 0.63% |
3,246,414
+1,517,165
| +88% | +$136M |
|
20
Arrow Electronics
ARW
$10.9B
| $270M | 0.61% |
2,467,162
+193,574
| +9% | +$22.6M |
|
21
Intel
INTC
$466B
| $269M | 0.61% |
7,307,773
+1,831,853
| +33% | +$79.3M |
|
22
AbbVie
ABBV
$458B
| $253M | 0.57% |
1,666,348
-131,592
| -7% | -$20.1M |
|
23
Coca-Cola
KO
$354B
| $249M | 0.56% |
3,981,653
+114,315
| +3% | +$7.25M |
|
24
Berkshire Hathaway Class B
BRK.B
$1.07T
| $237M | 0.54% |
869,696
-81,686
| -9% | -$25.6M |
|
25
EOG Resources
EOG
$78B
| $228M | 0.52% |
2,068,175
-197,845
| -9% | -$24.6M |
|
Similar funds
AQR Capital Management's Q2 2022 Portfolio in Review
As of Q2 2022, AQR Capital Management held 2,360 positions worth $44.2B, down 16% from $52.7B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
AQR Capital Management's Q2 2022 filing shows 150 new, 1,005 increased, 998 reduced and 187 closed positions. Its largest new stake was Fluor: 339,891 shares worth $7.86M. The largest sale was Thermo Fisher Scientific, an estimated $239M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 23% a quarter earlier, followed by Healthcare and Financials.
- AQR Capital Management's largest Q2 2022 buy was Fluor: 339,891 shares worth $7.86M.
- AQR Capital Management added most to Gilead Sciences in Q2 2022, an estimated $209M increase.
- AQR Capital Management's biggest Q2 2022 reduction was Thermo Fisher Scientific, cutting an estimated $239M.
- AQR Capital Management fully exited Roku in Q2 2022, selling an estimated $32.5M.
- AQR Capital Management's ten largest holdings make up 14% of its $44.2B portfolio in Q2 2022.
- AQR Capital Management opened 150 new positions and closed 187 in Q2 2022.
- AQR Capital Management's portfolio value fell 16% quarter-over-quarter to $44.2B.
Based on AQR Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.